esketamine hydrochloride

all catalysts(1)

News(9)

• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 11d ago
• Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
  Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
  biospace · 27d ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 1mo ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 1mo ago
• Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
  The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
  biopharma_dive · 1mo ago
• Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
  With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.
  biospace · 1mo ago
• J&J sees Spravato sales surge as psychedelic competitors loom
  Psychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.
  biospace · 1mo ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 1mo ago
• Another big premium hike on the horizon
  FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
  stat · 1mo ago